Hubcap_halo just posted in the stem cell thread that The Bill Gates Foundation, under "grant seekers," has a "negelected diseases" section. Hmmm, since they only accept letters of interest from 501(c)(3) and other tax-exempt organizations, I wonder if the CAA is the best agency to apply for this? What they do seems to fulfill the requirements. Then the CAA could > immediately fund getting rid of ANY and ALL references to CBT and GET being appropriate treatment & instead put out warnings against them, > as well as adding to the funding of good research that they've got going: add WPI, Ila Singh, the Lights, ........... > And partner with the documentary What about ME. >Maybe fund at home blood draws for those who want to contribute to the biobank and can't arrange for a local lab to come and do it for free. OR - set up a system/partnership for labs to do this? What other tax exempt groups are out there that are doing good things? Funding for Neglected Diseases Grants We accept letters of inquiry (LOI) for grants in our Neglected Diseases initiative. Occasionally, we issue requests for proposals (RFP). * We only accept LOI from 501(c)(3) and other tax-exempt organizations. * We do not fund grants to individuals. Funding Priorities We invest our efforts where we determine that effective and affordable methods will treat and eliminate the effects of the disease, and, in some cases, eradicate the disease itself. Often, the best approach is a combination of strategies integrating prevention and treatment. Because few of these diseases are addressed or well funded, weve formed a network of public, private, and nonprofit organizations. We form partnerships with organizations whose projects support the following strategies: * Improve diagnostics so that diseases can be detected early. * Develop vaccines and drug treatments that are safe, effective, and affordable. * Control the source of the disease. * Attempt to eliminate or eradicate some diseases entirely. * Advocate for public support to address these neglected diseases.